Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL185943 | 0.87 | AURKA (0.39) | CNR2DHODHMPO | |
| SCHEMBL10065634 | 0.86 | RAB9A (0.39) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| SCHEMBL185954 | 0.84 | DHODH (0.38) | CNR2KCNQ3KCNQ2DHODH | |
| SCHEMBL185709 | 0.82 | STK17A (0.38) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| SCHEMBL13160140 | 0.82 | CNR2 (0.42) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| Hydrochloric Acid SCHEMBL15456151 | 0.81 | STK17A (0.37) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| Hydrochloric Acid SCHEMBL2806736 | 0.81 | STK17A (0.37) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| SCHEMBL14865374 | 0.81 | CNR2 (0.39) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| SCHEMBL15455029 | 0.81 | CNR2 (0.38) | RAB9ACYP1A2CYP2D6CYP2C19TP53 | |
| SCHEMBL2812273 | 0.81 | CNR2 (0.38) | RAB9ACYP1A2CYP2D6CYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901127-B2 | Pyridazin derivatives as antagonists of the bradykinin B1 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-02 | — | — | US | disclosed |
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| CN-102414177-A | Compounds as bradykinin b1 antagonists | BOEHRINGER INGELHEIM INT | 2012-04-11 | — | — | CN | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | RAB9A 347/4885CYP1A2 892/4885CYP2D6 382/4885 |
| US-20140038977-A1 | PYRIDAZIN DERIVATIVES AS ANTAGONISTS OF THE BRADYKININ B1 RECEPTOR | BDKRB1, BDKRB2, HRH2 | RAB9A 4296/4885CYP1A2 508/4885CYP2D6 549/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | RAB9A 347/4885CYP1A2 892/4885CYP2D6 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.